Fujii et al reported that Uracil potentiated the antitumor activity of fluorouracil (5-FU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur). This effect was due to inhibition of the degradation of 5-FU, yet the phosphorylation of 5-FU was unaffected. The molar ratio of tegafur and uracil was 1:4, a combination that has since been widely prescribed in Japan for the treatment of cancer patients. We present here our experimental and clinical results when investigating the antineoplastic effects of this combination of drugs - known as UFT - and provide evidence that UFT is an effective treatment for patients with cancer.
|Number of pages
|9 SUPPL. 10
|Published - 1997
All Science Journal Classification (ASJC) codes
- Cancer Research